GlycoMimetics, Inc. GLYC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
31/100
Developing

Ranked against 712 peers in Biotechnology

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.89), with robust interest coverage.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.75), suggesting sticky customer base.

Key risks

  • Below-Peer Operating Efficiency Operating margin at 3.0th percentile indicates below-peer efficiency.
  • ROIC Below WACC or Peers ROIC at 0th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
17
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where GLYC ranks in Biotechnology

GlycoMimetics, Inc. ranks #502 of 713 scored companies in Biotechnology by moat score — the top 70%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
498 Tenax Therapeutics, Inc. TENX 32/100 Developing
499 OKYO Pharma Limited OKYO 31/100 Developing
500 Passage Bio, Inc. PASG 31/100 Developing
501 Precigen, Inc. PGEN 31/100 Developing
502 GlycoMimetics, Inc. GLYC 31/100 Developing
503 SeaStar Medical Holding Corpora ICU 31/100 Developing
504 ICUCW ICUCW 31/100 Developing
505 Onconetix, Inc. ONCO 31/100 Developing
506 Cabaletta Bio, Inc. CABA 31/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How GLYC scores on the Corporate Default defenses

Pricing Power

Score 17 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 3 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 32 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 44 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 45 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 31 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding GLYC's moat

What is GlycoMimetics, Inc.'s moat score?

GlycoMimetics, Inc. (GLYC) scores 31 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #502 of 713 scored companies in Biotechnology, the top 70%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (45/100) and its weakest is Cost Advantage (3/100).

How does GlycoMimetics, Inc. compare with other Biotechnology companies?

GlycoMimetics, Inc. ranks #502 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Precigen, Inc. (PGEN) at 31 just above it and SeaStar Medical Holding Corpora (ICU) at 31 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is GlycoMimetics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for GlycoMimetics, Inc.?

The Corporate Default template measures 6 defenses, and GLYC scores: Pricing Power (17), Cost Advantage (3), Customer Stickiness (32), Capital Efficiency (44), Resilience (45), Scale & Market Position (31). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000